YK012 clinical trials
Also written YK012.
How each study uses YK012 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the YK012 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2025 (2); 1 more planned to start later
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Excyte Biopharma Ltd (5)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test YK012.
- Dec 2026Study of YK012 in Primary Membranous NephropathyPhase 1 · Excyte Biopharma Ltd
- Dec 2026Study of YK012 in B-cell Acute Lymphoblastic LeukemiaPhase 1/2 · Excyte Biopharma Ltd
- Jun 2027Study of YK012 in Moderate to Severe Systemic Lupus ErythematosusPhase 1/2 · Excyte Biopharma Ltd
Studies
Open first, then newest update. How each study uses YK012 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Phase I Study of YK012 in Primary Membranous NephropathyNot yet recruitingPhase 1Excyte Biopharma LtdNCT07234474Written as YK012
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012RecruitingPhase 1Excyte Biopharma LtdNCT06565689Written as YK012
- Study of YK012 in B-cell Acute Lymphoblastic LeukemiaRecruitingPhase 1/2Excyte Biopharma LtdNCT06580301Written as YK012
- Study of YK012 in Moderate to Severe Systemic Lupus ErythematosusRecruitingPhase 1/2Excyte Biopharma LtdNCT07010835Written as YK012
- Study of YK012 in Primary Membranous NephropathyRecruitingPhase 1Excyte Biopharma LtdNCT06982729Written as YK012